Licensing, Acquisitions, and Other Arrangement- Acquisition of Nimble Therapeutics (Details) - USD ($) $ in Millions |
3 Months Ended | ||||
|---|---|---|---|---|---|
Mar. 31, 2025 |
Dec. 31, 2025 |
Jan. 23, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions | |||||
| Goodwill | $ 35,640 | $ 34,956 | $ 32,293 | ||
| Nimble Therapeutics, Inc. | |||||
| Collaborative Arrangements and Non-collaborative Arrangement Transactions | |||||
| Total consideration | $ 288 | ||||
| Upfront cash payment | $ 210 | ||||
| Contingent consideration | $ 78 | ||||
| Maximum future payments upon achievement of certain milestones | 130 | ||||
| Intangible assets - Developed product rights | 118 | ||||
| Goodwill | $ 170 |
| X | ||||||||||
- Definition Represents the maximum additional payment for research and early development of collaboration projects. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of liability recognized arising from contingent consideration in a business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of identifiable finite-lived intangible asset acquired in business combination and recognized at acquisition date. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|